. "Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era"@en . "17"^^ . . "Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era"@en . "Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era" . "000291328500003" . "11" . . "Clinical Breast Cancer" . "I, S" . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . . . "10"^^ . "RIV/00216208:11120/11:00003515" . "Adjuvant trastuzumab (AT) is known to significantly improve survival of women with HER2(+) early breast cancer. This study explores the use and nonuse of AT in early breast cancer, as well as the efficacy in a neoadjuvant and adjuvant population, within a routine clinical setting. Histopathology reports of invasive breast cancer resected at Imperial College Healthcare NHS Trust (ICHT) between January 2006 and December 2008 were reviewed. HER2(+) patients were identified and their case notes reviewed. In addition, patients who received AT at our center but underwent surgery elsewhere were included in the efficacy and safety analyses. The local HER2(+) rate was 13.1%, with 54.5% of these patients receiving AT. A total of 128 patients received AT (85 local and 43 referrals from elsewhere). Neoadjuvant chemotherapy (CT) followed by postoperative AT was associated with a significantly increased risk of recurrence compared with adjuvant CT and then AT (hazard ratio [HR] 18.6 [95% CI, 1.8-152.2]; P = .013)." . . . . "2" . "Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era" . . "Breast; Trastuzumab; Untreated; Neoadjuvant; Adjuvant"@en . "Adjuvant trastuzumab (AT) is known to significantly improve survival of women with HER2(+) early breast cancer. This study explores the use and nonuse of AT in early breast cancer, as well as the efficacy in a neoadjuvant and adjuvant population, within a routine clinical setting. Histopathology reports of invasive breast cancer resected at Imperial College Healthcare NHS Trust (ICHT) between January 2006 and December 2008 were reviewed. HER2(+) patients were identified and their case notes reviewed. In addition, patients who received AT at our center but underwent surgery elsewhere were included in the efficacy and safety analyses. The local HER2(+) rate was 13.1%, with 54.5% of these patients receiving AT. A total of 128 patients received AT (85 local and 43 referrals from elsewhere). Neoadjuvant chemotherapy (CT) followed by postoperative AT was associated with a significantly increased risk of recurrence compared with adjuvant CT and then AT (hazard ratio [HR] 18.6 [95% CI, 1.8-152.2]; P = .013)."@en . . "1"^^ . . . "RIV/00216208:11120/11:00003515!RIV12-MSM-11120___" . "Goji\u0161, Ond\u0159ej" . "1526-8209" . . . . "http://dx.doi.org/10.1016/j.clbc.2011.03.001" . "210374" . "[E044C312C6E9]" . . "Palmieri, Carlo" . "10.1016/j.clbc.2011.03.001" . . "11120" . .